Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Medicine and Dentistry New Jersey Ligand Pharmaceuticals |
---|---|
Information provided by: | University of Medicine and Dentistry New Jersey |
ClinicalTrials.gov Identifier: | NCT00151008 |
To determine if bexarotene gel with NBUVB phototherapy is more effective than placebo plus NBUVB for moderate to severe plaque-type psoriasis.
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: Bexarotene/NBUVB vs placebo NBUVB |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | Investigator-Initiated, Double Blind, Vehicle-Controlled, Bilateral Comparison Trial of Bexarotene (Targretin) Gel 1% vs. Vehicle Gel in Combination With Narrow Band UVB Phototherapy for Moderate to Severe Psoriasis Vulgaris |
Estimated Enrollment: | 35 |
Study Start Date: | November 2003 |
Estimated Study Completion Date: | August 2005 |
Subjects will be applying active gel or placebo to target lesions to each side of the body in a blinded manner. They will start at three times a week and increase to daily or even twice a day regimen if tolerated. After 2 weeks of application, NBUVB will be added to treatment regimen (whole body, three times a week). Total study time is 10 weeks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Study ID Numbers: | 4405 |
Study First Received: | September 6, 2005 |
Last Updated: | August 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00151008 |
Health Authority: | United States: Institutional Review Board |
psoriasis bexarotene narrow band UVB |
Skin Diseases Bexarotene Psoriasis Skin Diseases, Papulosquamous |
Anticarcinogenic Agents Antineoplastic Agents Therapeutic Uses |
Physiological Effects of Drugs Protective Agents Pharmacologic Actions |